$MRNS
MARINUS PHARMACEUTICALS, INC.

2021 Q4 Form 10-K Financial Statement

#000155837022004279 Filed on March 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $1.520M $15.35M $1.550M
YoY Change -1.94% 793.19%
Cost Of Revenue $1.478M
YoY Change
Gross Profit $13.87M
YoY Change
Gross Profit Margin 90.37%
Selling, General & Admin $10.62M $37.28M $6.010M
YoY Change 76.74% 100.96% 103.04%
% of Gross Profit 268.83%
Research & Development $18.01M $73.52M $13.04M
YoY Change 38.14% 43.86% 4.24%
% of Gross Profit 530.18%
Depreciation & Amortization $93.00K $355.0K $90.00K
YoY Change 3.33% 6.29% 12.5%
% of Gross Profit 2.56%
Operating Expenses $28.64M $73.52M $19.05M
YoY Change 50.32% 43.86% 23.14%
Operating Profit -$96.93M
YoY Change 42.68%
Interest Expense -$1.530M $2.582M $40.00K
YoY Change -3925.0% 416.4% -42.86%
% of Operating Profit
Other Income/Expense, Net $541.0K $657.0K -$10.00K
YoY Change -5510.0% -1875.68% 0.0%
Pretax Income -$28.31M -$98.78M -$17.47M
YoY Change 62.02% 46.39% 13.37%
Income Tax
% Of Pretax Income
Net Earnings -$28.31M -$98.78M -$17.47M
YoY Change 62.02% 46.39% 13.37%
Net Earnings / Revenue -1862.17% -643.7% -1127.1%
Basic Earnings Per Share -$2.69
Diluted Earnings Per Share -$769.4K -$2.69 -$640.6K
COMMON SHARES
Basic Shares Outstanding 36.77M 36.70M 30.59M
Diluted Shares Outstanding 36.66M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.9M $122.9M $140.0M
YoY Change -12.2% -12.2% 52.67%
Cash & Equivalents $122.9M $122.9M $138.5M
Short-Term Investments $0.00 $0.00 $1.500M
Other Short-Term Assets $5.565M $5.565M $4.600M
YoY Change 20.98% 20.98% 84.0%
Inventory $0.00
Prepaid Expenses
Receivables $2.629M $3.186M $1.646M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $131.7M $131.7M $146.3M
YoY Change -9.97% -9.99% 55.38%
LONG-TERM ASSETS
Property, Plant & Equipment $2.499M $4.199M $1.945M
YoY Change 28.48% 7.67% -14.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.663M $963.0K $2.250M
YoY Change 18.36% 221.0% -7.9%
Total Long-Term Assets $5.162M $5.162M $4.195M
YoY Change 23.05% 22.9% -10.9%
TOTAL ASSETS
Total Short-Term Assets $131.7M $131.7M $146.3M
Total Long-Term Assets $5.162M $5.162M $4.195M
Total Assets $136.8M $136.8M $150.5M
YoY Change -9.05% -9.08% 52.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.126M $3.126M $2.211M
YoY Change 41.38% 42.09% -19.98%
Accrued Expenses $16.21M $16.21M $8.518M
YoY Change 90.27% 90.67% 61.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $40.57M $40.57M $10.73M
YoY Change 278.1% 279.12% 33.59%
LONG-TERM LIABILITIES
Long-Term Debt $40.81M $40.81M $0.00
YoY Change
Other Long-Term Liabilities $1.979M $1.979M $2.500M
YoY Change -20.84% -20.84% -16.67%
Total Long-Term Liabilities $42.79M $42.79M $2.500M
YoY Change 1611.52% 1611.52% -16.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.57M $40.57M $10.73M
Total Long-Term Liabilities $42.79M $42.79M $2.500M
Total Liabilities $83.35M $83.35M $13.26M
YoY Change 528.47% 526.72% 19.78%
SHAREHOLDERS EQUITY
Retained Earnings -$410.7M -$311.9M
YoY Change 31.67% 32.41%
Common Stock $37.00K $37.00K
YoY Change 0.0% 68.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $7.307K $7.307K
Shareholders Equity $53.49M $53.49M $137.2M
YoY Change
Total Liabilities & Shareholders Equity $136.8M $136.8M $150.5M
YoY Change -9.05% -9.08% 52.22%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$28.31M -$98.78M -$17.47M
YoY Change 62.02% 46.39% 13.37%
Depreciation, Depletion And Amortization $93.00K $355.0K $90.00K
YoY Change 3.33% 6.29% 12.5%
Cash From Operating Activities -$21.75M -$55.48M -$16.40M
YoY Change 32.62% -8.92% 0.92%
INVESTING ACTIVITIES
Capital Expenditures -$721.0K -$2.889M $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.474M $2.480M
YoY Change -100.0% -299.19% 24.62%
Cash From Investing Activities -$721.0K -$1.415M $2.480M
YoY Change -129.07% 91.73% 26.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 297.0K 41.31M 65.09M
YoY Change -99.54% -62.18% -4.38%
NET CHANGE
Cash From Operating Activities -21.75M -55.48M -16.40M
Cash From Investing Activities -721.0K -1.415M 2.480M
Cash From Financing Activities 297.0K 41.31M 65.09M
Net Change In Cash -22.17M -15.58M 51.17M
YoY Change -143.33% -132.76% -4.85%
FREE CASH FLOW
Cash From Operating Activities -$21.75M -$55.48M -$16.40M
Capital Expenditures -$721.0K -$2.889M $0.00
Free Cash Flow -$21.03M -$52.59M -$16.40M
YoY Change 28.23% -13.67% 1.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36663340
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27270055
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36663340
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19087
CY2021 dei City Area Code
CityAreaCode
484
CY2021 dei Local Phone Number
LocalPhoneNumber
801-4670
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
MRNS
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27270055
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001267813
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherAccruedLiabilitiesNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherAccruedLiabilitiesNoncurrent
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.69
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.80
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.69
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.80
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36576
CY2021 dei Entity Registrant Name
EntityRegistrantName
Marinus Pharmaceuticals, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0198082
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
5 Radnor Corporate Center, Suite 500
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
100 Matsonford Road
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Radnor
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
451604966
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37003419
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122927000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138509000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
1474000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2629000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1646000
CY2021Q4 mrns Contract With Customer Asset Liability Net
ContractWithCustomerAssetLiabilityNet
557000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5565000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4638000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
131678000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
146267000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2499000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1945000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2663000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2250000
CY2021Q4 us-gaap Assets
Assets
136840000
CY2020Q4 us-gaap Assets
Assets
150462000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3126000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2211000
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
21233000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16207000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8518000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40566000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10729000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
40809000
CY2021Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1979000
CY2020Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
2534000
CY2021Q4 us-gaap Liabilities
Liabilities
83354000
CY2020Q4 us-gaap Liabilities
Liabilities
13263000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
4302000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
4469000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36797561
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36790254
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36585767
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36578460
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
459852000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
444622000
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7307
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7307
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410705000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-311929000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
53486000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
137199000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136840000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
150462000
CY2021 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
6358000
CY2020 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1718000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8987000
CY2021 us-gaap Revenues
Revenues
15345000
CY2020 us-gaap Revenues
Revenues
1718000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73520000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51106000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37278000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18549000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1478000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
112276000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
69655000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-96931000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-67937000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
80000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
499000
CY2021 us-gaap Interest Expense
InterestExpense
2582000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
657000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-98776000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-67475000
CY2020 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
8880000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-98776000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76355000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.69
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.80
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36697171
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27270055
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
59569000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7642000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1020000
CY2020 mrns Stock Issued During Period Value Equity Distribution Agreement
StockIssuedDuringPeriodValueEquityDistributionAgreement
489000
CY2020 mrns Transfer Of Convertible Preferred Stock To Permanent Equity Value
TransferOfConvertiblePreferredStockToPermanentEquityValue
8745000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
19456000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-67475000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
137199000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13867000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1199000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-98776000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
53486000
CY2021 us-gaap Profit Loss
ProfitLoss
-98776000
CY2020 us-gaap Profit Loss
ProfitLoss
-67475000
CY2021 us-gaap Depreciation
Depreciation
355000
CY2020 us-gaap Depreciation
Depreciation
334000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
549000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
13867000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7642000
CY2021 mrns Noncash Contract Asset Operating Activities
NoncashContractAssetOperatingActivities
105000
CY2021 mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
312000
CY2020 mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
264000
CY2021 mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
309000
CY2020 mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
362000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-243000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
930000
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-3000
CY2021 mrns Increase Decrease In Contract With Customer Refund Liability
IncreaseDecreaseInContractWithCustomerRefundLiability
22163000
CY2021 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
452000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
853000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3919000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7841000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1877000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55477000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60912000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
1474000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
8193000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
8931000
CY2021 mrns Payments For Deposit And Property And Equipment
PaymentsForDepositAndPropertyAndEquipment
1793000
CY2021 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
1096000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1415000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-738000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1199000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1020000
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
40259000
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
148000
CY2020 mrns Proceeds From Equity Offerings Net
ProceedsFromEquityOfferingsNet
108196000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41310000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109216000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15582000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
47566000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138509000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90943000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122927000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138509000
CY2021 mrns Contractual Exit Fee Included In Notes Payable
ContractualExitFeeIncludedInNotesPayable
900000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
43000
CY2020 mrns Financing In Accounts Payable And Accrued Expenses
FinancingInAccountsPayableAndAccruedExpenses
-148000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-98800000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410700000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.</p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-98776000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-67475000
CY2020 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
8880000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-98776000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76355000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36697171
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27270055
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.69
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.80
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2535000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5679880
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4482863
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3893000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3077000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1394000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1132000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2499000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1945000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5830000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4097000
CY2021Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
8217000
CY2020Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
2452000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1311000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
927000
CY2021Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
556000
CY2020Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
510000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
532000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16207000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8518000
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P78M
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P60M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P45M
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1700000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2000000.0
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2500000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3000000.0
CY2021 us-gaap Lease Cost
LeaseCost
600000
CY2020 us-gaap Lease Cost
LeaseCost
600000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
100000
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.110
CY2020 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
807000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
823000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
840000
CY2021Q4 mrns Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
643000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3113000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
578000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
556000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1979000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2535000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13588000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7459000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
45000000
CY2021Q4 mrns Contractual Term Loan Exit Fees
ContractualTermLoanExitFees
900000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
5091000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
40809000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6825000
CY2021Q4 mrns Long Term Debt Maturities Repayments Of Principal In Year Four And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter
38175000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
45000000
CY2021Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
700000
CY2021 mrns Defined Contribution Plan Employer Contribution Vesting Period
DefinedContributionPlanEmployerContributionVestingPeriod
P4Y
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-98776000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-67475000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-98776000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67475000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
81719000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
59819000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
272000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
219000
CY2021Q4 mrns Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
251000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5944000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4270000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
16216000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
11906000
CY2021Q4 mrns Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
610000
CY2020Q4 mrns Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
879000
CY2021Q4 mrns Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
11437000
CY2020Q4 mrns Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
15891000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
116458000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
93000000
CY2021Q4 mrns Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
399000
CY2020Q4 mrns Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
569000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
99000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
252000
CY2021Q4 us-gaap Deferred Tax Liabilities Tax Deferred Income
DeferredTaxLiabilitiesTaxDeferredIncome
212000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
710000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
821000
CY2021Q4 mrns Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
115748000
CY2020Q4 mrns Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
92179000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
115748000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
92179000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
23600000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
39700000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 mrns Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2021Q4 mrns Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.007
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.022
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.076
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.043
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.047
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.028
CY2020 mrns Effective Income Tax Rate Reconciliation Capitalized Research And Development Expenses
EffectiveIncomeTaxRateReconciliationCapitalizedResearchAndDevelopmentExpenses
0.262
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.240
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.588
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000

Files In Submission

Name View Source Status
0001558370-22-004279-index-headers.html Edgar Link pending
0001558370-22-004279-index.html Edgar Link pending
0001558370-22-004279.txt Edgar Link pending
0001558370-22-004279-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrns-20211231.xsd Edgar Link pending
mrns-20211231x10k.htm Edgar Link pending
mrns-20211231x10k001.jpg Edgar Link pending
mrns-20211231x10k004.jpg Edgar Link pending
mrns-20211231x10k_htm.xml Edgar Link completed
mrns-20211231xex10d10.htm Edgar Link pending
mrns-20211231xex10d34.htm Edgar Link pending
mrns-20211231xex10d34001.jpg Edgar Link pending
mrns-20211231xex10d35.htm Edgar Link pending
mrns-20211231xex10d35001.jpg Edgar Link pending
mrns-20211231xex10d36.htm Edgar Link pending
mrns-20211231xex10d36001.jpg Edgar Link pending
mrns-20211231xex21.htm Edgar Link pending
mrns-20211231xex23d1.htm Edgar Link pending
mrns-20211231xex31d1.htm Edgar Link pending
mrns-20211231xex31d2.htm Edgar Link pending
mrns-20211231xex32d1.htm Edgar Link pending
mrns-20211231xex4d3.htm Edgar Link pending
mrns-20211231_cal.xml Edgar Link unprocessable
mrns-20211231_def.xml Edgar Link unprocessable
mrns-20211231_lab.xml Edgar Link unprocessable
mrns-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending